Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Lexicon Pharmaceuticals Stock Quote

Lexicon Pharmaceuticals (NASDAQ: LXRX)

$1.87
(-5.1%)
-$0.10
Price as of April 15, 2024, 4:00 p.m. ET

Lexicon Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
LXRX -19.92% -67.55% -20.13% -98%
S&P +23.57% +76.22% +11.98% +234%

Lexicon Pharmaceuticals Company Info

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

News & Analysis

The Fool has written over 100 articles on Lexicon Pharmaceuticals.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.